Aura Biosciences
AURA
57 hedge funds and large institutions have $233M invested in Aura Biosciences in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
16% more funds holding
Funds holding: 49 → 57 (+8)
0.27% more ownership
Funds ownership: 66.06% → 66.32% (+0.27%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $250M → $233M (-$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6M |
| 2 |
Citigroup
New York
|
+$3.85M |
| 3 |
BlackRock
New York
|
+$2.89M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.85M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.86M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.44M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.38M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$297K |
AURA Hedge Fund Activity: Q1 2023 in Review
57 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2023, worth a combined $233M — down 7% from $250M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AURA positions and 6 closed out — a net gain of 8 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6M. The largest seller was Artal Group, exiting entirely with an estimated $4.3M sold.
- 57 institutional investors held Aura Biosciences (AURA) as of Q1 2023, up from 49 in Q4 2022.
- Funds reported $233M of Aura Biosciences stock for Q1 2023, down 7% quarter-over-quarter.
- 14 funds opened new Aura Biosciences positions in Q1 2023 and 6 closed out, a net change of +8 holders.
- The largest Aura Biosciences buyer in Q1 2023 was Adage Capital Partners, an estimated $6M added.
- The largest Aura Biosciences seller in Q1 2023 was Artal Group, an estimated $4.3M sold.
Based on aggregated 13F filings for Q1 2023.